ADAM17 and ovarian carcinoma: Hugendieck et al. have also shown that ADAM17 on TEVs isolated from the malignant ascites of ovarian cancer patients is responsible for the shedding of AREG from target tumor cells, representing another example of ADAM17-mediated “trans shedding” [132].